DrugPatentWatch Database Preview
VIIV Company Profile
Email this page to a colleague
What is the competitive landscape for VIIV, and when can generic versions of VIIV drugs launch?
VIIV has twenty-four approved drugs.
There are fifteen US patents protecting VIIV drugs.
There are five hundred and forty-nine patent family members on VIIV drugs in sixty-seven countries and one hundred and seventy-eight supplementary protection certificates in eighteen countries.
Summary for VIIV
| International Patents: | 549 |
| US Patents: | 15 |
| Tradenames: | 17 |
| Ingredients: | 16 |
| NDAs: | 24 |
| PTAB Cases with VIIV as patent owner: | See PTAB cases with VIIV as patent owner |
Drugs and US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | VOCABRIA | cabotegravir sodium | TABLET;ORAL | 212887-001 | Jan 21, 2021 | RX | Yes | Yes | 8,410,103 | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Viiv Hlthcare | TRIZIVIR | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 021205-001 | Nov 14, 2000 | AB | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | ||||
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try it Free | ⤷ Try it Free | |||||
| Viiv Hlthcare | JULUCA | dolutegravir sodium; rilpivirine hydrochloride | TABLET;ORAL | 210192-001 | Nov 21, 2017 | RX | Yes | Yes | 10,426,780 | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-003 | Jun 9, 2016 | RX | Yes | No | 9,242,986 | ⤷ Try it Free | Y | Y | ⤷ Try it Free | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIV
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | EPIVIR | lamivudine | SOLUTION;ORAL | 020596-001 | Nov 17, 1995 | 5,047,407*PED | ⤷ Try it Free |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 6,113,920*PED | ⤷ Try it Free |
| Viiv Hlthcare | COMBIVIR | lamivudine; zidovudine | TABLET;ORAL | 020857-001 | Sep 26, 1997 | 7,119,202*PED | ⤷ Try it Free |
| Viiv Hlthcare | RETROVIR | zidovudine | SOLUTION;ORAL | 019910-001 | Sep 28, 1989 | 4,833,130 | ⤷ Try it Free |
| Viiv Hlthcare | LEXIVA | fosamprenavir calcium | SUSPENSION;ORAL | 022116-001 | Jun 14, 2007 | 6,436,989*PED | ⤷ Try it Free |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
| ➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
| ➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
| ➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
| ➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
| ➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
| ➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
| ➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
| ➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
| ➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
| ➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
International Patents for VIIV Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2007529519 | ⤷ Try it Free |
| Mexico | 2012008774 | ⤷ Try it Free |
| Brazil | 0110955 | ⤷ Try it Free |
| Israel | 245182 | ⤷ Try it Free |
| Singapore | 182614 | ⤷ Try it Free |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIIV Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | PA2016045 | Lithuania | ⤷ Try it Free | PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 1663240 | 15C0071 | France | ⤷ Try it Free | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE TELLES QUE LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE AINSI QUE D'EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
| 1632232 | 93385 | Luxembourg | ⤷ Try it Free | PRODUCT NAME: COMBINAISON DE CHLORHYDRATE DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, EMTRICITABINE, ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE |
| 1632232 | PA2016043 | Lithuania | ⤷ Try it Free | PRODUCT NAME: RILPIVIRINO HIDROCHLORIDAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
| 1419152 | 12C0035 | France | ⤷ Try it Free | PRODUCT NAME: RILPIVIRINE AINSI QUE SES FORMES THERAPEUTIQUEMENT PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS D'ADDITION DE RILPIVIRINE PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/11/736/001 20111128 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
